Back to results
US 12,616,759 B2Granted
Uses of labeled HSP90 inhibitors
AssigneeSloan-Kettering Institute for Cancer Research
InventorsGabriela Chiosis, Nagavarakishore Pillarsetty, Jason S. Lewis, Steven M. Larson, Tony Taldone, Mary L. Alpaugh, Erica M. Gomes-DaGama
Life of this patent
Estimating the term…
Abstract
This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.
Claims3
A method for determining whether a tumor in a subject will respond to therapy with an HSP90 inhibitor which comprises the following steps:
- (a) administering to the subject a radiolabeled HSP90 inhibitor;
- (b) measuring the amount of radiolabeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample;
- and
- (c) comparing the amount of radiolabeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample measured in step (b) to the amount of radiolabeled HSP90 inhibitor bound to a reference;
- wherein a greater amount of radiolabeled HSP90 inhibitor bound to the tumor or the tumor cells measured in step (b) as compared with the reference amount indicates the tumor will likely respond to the HSP90 inhibitor;
- wherein the radiolabeled HSP90 inhibitor is a compound or a pharmaceutically acceptable salt thereof of
3 more elements
A compound or a pharmaceutically acceptable salt thereof selected from:
Dependencies are inferred from the claim text.